#### This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30 PM

# **BUY** State Bank of India

## Margin decelerates, but RoA accelerates >1%

### BFSI - Banks > Result Update > August 5, 2023

Notwithstanding the slower growth and sharp margin contraction, SBI continued to deliver a strong PAT beat, at Rs168bn (Emkay: Rs149bn)/1.2% RoA in 1Q, on robust treasury gains, lower overheads and LLP. Though NIM contraction for SBI in 1Q was relatively higher (27bps QoQ to 3.3%) vs private peers (12-20bps), we believe most banks on cumulative basis would in near term will exhibit similar margin contraction. Bank guides for 13-14% growth in FY24E led by Retail which, along with better LDR/consumption of on-balance-sheet liquidity, should help sustain FY24E margin at 3.4-3.5% (reported). Despite the lower CET 1 at 10.2%, Bank believes that it can fund current growth via internal accruals.

Factoring-in the 1Q beat, we raise our earnings by 2-3% for FY24-26E and expect the bank to deliver a healthy 1-1.1% RoA/17-19% RoE without any capital raise. We retain BUY on the stock with TP of Rs700/share, valuing the standalone bank at 1.2x Jun-25E ABV and subs/investments at Rs185/share.

State Bank of India:	<b>Financial S</b>	Snapshot (S	tandalone)		
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	390,943	502,325	620,720	667,687	715,389
Loan growth (%)	11.6	17.0	13.1	14.4	16.0
NII growth (%)	9.0	20.0	12.4	11.0	11.1
NIM (%)	2.8	3.0	3.0	3.0	3.0
PPOP growth (%)	5.2	11.2	15.3	11.8	14.9
Adj. EPS (Rs)	43.8	56.3	69.6	74.8	80.2
Adj. EPS growth (%)	91.5	28.5	23.6	7.6	7.1
Adj. BV (INR)	264.2	318.0	374.6	433.3	492.0
Adj. BVPS growth (%)	16.3	20.4	17.8	15.6	13.6
RoA (%)	0.8	1.0	1.1	1.0	1.0
RoE (%)	16.1	18.1	19.1	17.8	16.6
P/E (x)	8.8	6.9	5.6	5.2	4.8
P/ABV (x)	1.6	1.3	1.1	0.9	0.8

Source: Company, Emkay Research

#### Slower growth, higher deposit cost led to sharp margin contraction

SBI reported relatively slower growth at 15% YoY/1.1% QoQ vs the system's at 16.2% YoY/5.2% QoQ, mainly due to de-growth in the overseas book amid rising dislocation and muted corporate growth (partly due to pay-off by a large corporate). However, retail growth remains strong at 17% YoY/2% QoQ; within which in Auto, Gold and X-press credit continues to grow at a healthy pace, while mortgages growth was moderate. Deposit growth was largely in line with the system's at 12% YoY/2.4% QoQ, which led to slightly lower LDR at 71%. This, coupled with flattish investment yields and sharp jump in deposit cost, led to a 27bps QoQ contraction in NIM to 3.3%. Going forward, Bank guides for 13-14% credit growth led by retail in FY24E which, along with better LDR/consumption of on-balance-sheet liquidity, should help sustain margins at 3.4-3.5% (reported) in FY24E.

#### Slippages inch up due to seasonal factors, but NPAs remain stable

Gross slippages were higher (in line with our expectations) at Rs79bn/1.1% of loans (due to higher slippages from Agri at 3.5% and from SME at 2.6%), leading to nearly flat GNPA ratio of 2.8%. However, the bank has already recovered ~21% of the slippages in the Jul-2023 itself which should thus lead to steady reduction in NPAs during 2Q. The restructured pool continued to moderate, to Rs226bn/0.7% of loans vs 0.8% in Q4. On personal loans, the bank allays any asset-quality concerns that it claims are largely (95%) built towards government employees with steady salary flow.

#### We retain BUY

Factoring-in the 1Q beat, we raise our earnings by 2-3% for FY24-26E and expect the bank to deliver a healthy 1-1.1% RoA/17-19% RoE without any capital raise. We retain BUY on the stock with TP of Rs700/share, valuing the standalone bank at 1.2x Jun-25E ABV and subs/investments at Rs185/share. Despite the lower CET 1 at 10.2%, Bank believes that it can fund the current growth through internal accruals and is thus in no hurry to raise capital. **Key risks:** Severe macro dislocation and a prolonged elevated-rate environment hurting margins, leading to growth/asset quality disruption.



Ticker

#### **TARGET PRICE (Rs): 700**

Target Price – 12M	Jun-24
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	22.1
CMP (04-Aug-23) (Rs)	573.3

#### Stock Data

Stock Data	TICKET
52-week High (Rs)	630
52-week Low (Rs)	499
Shares outstanding (mn)	8,924.6
Market-cap (Rs bn)	5,116
Market-cap (USD mn)	61,763
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	17
ADTV-3M (Rs mn)	9,983.1
ADTV-3M (USD mn)	120.5
Free float (%)	43.0
Nifty-50	19,517
INR/USD	82.8
Shareholding, Jun-23	
Promoters (%)	56.9
FPIs/MFs (%)	10.3/24.6

Price Performance									
(%)	1M	3M	12M						
Absolute	(2.7)	(1.2)	7.5						
Rel. to Nifty	(3.3)	(7.5)	(4.3)						



#### Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480


#### Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


## **Story in Charts**

Exhibit 1: Credit growth moderates to 15% vs systemic credit growth at 16%




Source: Company, Emkay Research

#### Exhibit 3: CASA cannibalization leads to moderation in CASA ratio




Source: Company, Emkay Research

#### Exhibit 5: GNPA ratio - Improvement trend stalled in 1Q, but should decelerate, as recoveries accelerate




Source: Company, Emkay Research

#### Exhibit 2: NIM contracted by 27bps QoQ to 3.3%




Source: Company, Emkay Research

#### Exhibit 4: Slippages were seasonally elevated



Source: Company, Emkay Research

Exhibit 6: Higher other income, lower opex/LLP led to RoA of >1%



Source: Company, Emkay Research

This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: SBI to report a healthy RoA/RoE trajectory (without factoring-in capital raise)






Exhibit 8: We value the standalone bank at 1.2x Jun-25E ABV and subsidiaries/investments at Rs185 per share



Source: Emkay Research

Source: Emkay Research





Source: Company, Emkay Research

This report is intended for team emkay @whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Exhibit 10: Actuals vs Estimates (Q1FY24)

Rs mn	Actuals	Estir	nates	Vai	iation	Comments
Actual		Emkay	Consensus	Emkay	Consensus	
Net income	509,683	490,379	470,422	4%	8%	Lower margins, offset by higher other income, led to a beat
PPOP	252,969	232,743	233,045	9%	9%	Higher net income and lower opex led to a beat
РАТ	168,843	148,737	143,915	14%	17%	Lower LLP led to a beat

Source: Company, Emkay Research

## Exhibit 11: Quarterly Summary

(Rs mn)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	YoY (%)	QoQ (%)	FY23A	FY24E	YoY (%)
Interest Earned	726,764	798,596	866,160	929,511	959,755	32	3	3,321,031	4,073,443	23
Interest Exp	414,804	446,762	485,474	525,586	570,705	38	9	1,872,626	2,445,655	31
Net Interest Income	311,959	351,834	380,686	403,925	389,050	25	-4	1,448,405	1,627,788	12
Global NIMs (reported)	3.02	3.32	3.50	3.60	3.33	31bps	-27bps	3.01	3.05	4bps
Non-interest Income	23,122	88,743	114,677	139,614	120,634	422	-14	366,156	464,202	27
Operating Expenses	207,556	229,377	243,171	297,328	256,714	24	-14	977,431	1,127,048	15
Pre Provisioning Profit	127,526	211,200	252,193	246,211	252,969	98	3	837,130	964,941	15
Provision & Contingencies	43,924	30,387	57,606	33,157	25,013	-43	-25	165,073	135,102	-18
PBT	83,602	180,814	194,587	213,054	227,956	173	7	672,057	829,839	23
Income Tax Expense (Gain)	22,921	48,168	52,534	46,109	59,113	158	28	169,732	209,120	23
Net Profit/(Loss)	60,681	132,645	142,053	166,945	168,843	178	1	502,325	620,720	24
Gross NPA (%)	3.91	3.52	3.14	2.78	2.76	-115bps	-2bps	2.78	2.19	-59bps
Net NPA (%)	1.00	0.80	0.77	0.67	0.71	-29bps	4bps	0.67	0.56	-11bps
Deposits (Rs bn)	40,457	41,903	42,136	44,238	45,312	12	2	44,238	48,986	11
Net Advances (Rs bn)	28,152	29,513	30,582	31,993	32,350	15	1	31,993	36,169	13

Source: Company, Emkay Research

## Exhibit 12: Revision in Estimates

Y/E Mar (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net interest income	1,667,999	1,627,788	-2.4%	1,851,097	1,807,208	-2.4%	2,066,967	2,007,968	-2.9%
PPOP	996,920	964,941	-3.2%	1,130,093	1,078,925	-4.5%	1,285,649	1,239,190	-3.6%
PAT	630,987	620,720	-1.6%	682,583	667,687	-2.2%	725,135	715,389	-1.3%
EPS (Rs)	70.7	69.6	-1.6%	76.5	74.8	-2.2%	81.3	80.2	-1.3%
BV (Rs)	393.2	391.5	-0.4%	455.2	451.3	-0.8%	520.9	515.5	-1.0%

Source: Emkay Research

Exhibit 13: Key assumption	ons			
(%)	FY23A	FY24E	FY25E	FY26E
Loan Growth	17.0	13.1	14.4	16.0
Deposit Growth	9.2	10.7	12.9	16.0
NIM	3.0	3.0	3.0	3.0
GNPA	2.8	2.2	1.8	1.9
Credit Cost	0.5	0.5	0.5	0.7

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Exhibit 14: Key ratios and trends

	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24
Loans (Rs bn)	24,319	24,432	25,784	27,340	28,152	29,513	30,582	31,993	32,350
Loan growth (YoY)	5.8	6.5	8.9	11.6	15.8	20.8	18.6	17.0	14.9
Loan growth (QoQ)	-0.7	0.5	5.5	6.0	3.0	4.8	3.6	4.6	1.1
Loan composition (%)									
Corporate	32.5	31.0	30.4	31.8	31.0	31.1	30.2	30.6	30.4
Retail	35.9	37.0	36.9	36.7	36.7	36.4	36.8	36.9	37.2
SME	11.7	11.5	11.9	11.2	11.1	10.7	11.5	11.2	11.4
Overseas	15.1	15.3	15.5	15.0	16.0	16.5	15.9	15.4	14.9
Agri	4.9	5.2	5.3	5.3	5.1	5.3	5.6	5.9	6.1
Liability Profile & Margins (%)									
CASA	44.6	44.8	44.2	43.8	43.7	42.9	42.7	42.1	41.2
CA	6.1	6.6	5.9	6.5	5.8	5.6	5.4	6.4	5.7
SA	38.5	38.2	38.3	37.3	37.9	37.4	37.3	35.7	35.5
Global NIM	2.92	3.09	3.11	3.12	3.02	3.32	3.50	3.60	3.33
Domestic NIM	3.15	3.33	3.35	3.36	3.23	3.39	3.49	3.58	3.47
Asset Quality									
GNPA (%)	5.3	4.9	4.5	4.0	3.9	3.5	3.1	2.8	2.8
NNPA (%)	1.7	1.5	1.3	1.0	1.0	0.8	0.8	0.7	0.7
PCR (%)	67.9	70.1	71.2	75.0	75.1	77.9	76.1	76.4	74.8
Slippages (Rs bn)	163	42	26	36	101	24	32	35	79
Slippages (%)	2.8	0.7	0.4	0.6	1.7	0.4	0.5	0.5	1.1
Capital Adequacy									
CAR (%)	13.7	13.4	13.2	13.8	13.4	13.5	13.3	14.7	14.6
Tier I (%)	11.4	11.0	10.9	11.4	11.2	11.1	10.8	12.1	12.0
CET 1 (%)	9.9	10.4	10.3	9.9	9.7	9.5	9.3	10.3	10.2
ROE decomposition on total assets (%)									
NII	2.4	2.7	2.6	2.5	2.5	2.8	2.9	3.0	2.8
Other Income (Ex Treasury)	0.9	0.7	0.7	1.0	0.7	0.7	0.6	0.9	0.6
Treasury	0.2	0.0	0.0	0.0	-0.5	0.0	0.2	0.1	0.3
Opex	1.8	2.5	1.8	1.9	1.7	1.8	1.8	2.2	1.9
PPOP	1.7	0.9	1.6	1.6	1.0	1.7	1.9	1.8	1.8
Provisioning Cost	0.9	0.0	0.6	0.6	0.4	0.2	0.4	0.2	0.2
РВТ	0.8	0.9	1.0	1.0	0.7	1.4	1.5	1.6	1.6
Tax	0.2	0.2	0.3	0.3	0.2	0.4	0.4	0.3	0.4
ROA	0.6	0.7	0.7	0.7	0.5	1.0	1.1	1.2	1.2
Leverage (x)	17.6	17.5	17.5	17.6	17.5	17.1	16.8	16.7	16.5
ROE	10.1	11.5	12.4	13.1	8.5	17.8	18.2	20.6	20.1

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## State Bank of India: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	2,754,573	3,321,031	4,073,443	4,411,358	4,813,602
Interest Expense	1,547,497	1,872,626	2,445,655	2,604,150	2,805,633
Net interest income	1,207,076	1,448,405	1,627,788	1,807,208	2,007,968
NII growth (%)	9.0	20.0	12.4	11.0	11.1
Other income	405,639	366,156	464,202	513,315	594,036
Total Income	1,612,715	1,814,561	2,091,990	2,320,523	2,602,005
Operating expenses	859,792	977,431	1,127,048	1,241,598	1,362,815
РРОР	752,923	837,130	964,941	1,078,925	1,239,190
PPOP growth (%)	5.2	11.2	15.3	11.8	14.9
Core PPOP	720,705	850,674	898,339	1,005,751	1,141,007
Provisions & contingencies	244,521	165,073	135,102	186,295	282,787
PBT	508,402	672,057	829,839	892,630	956,402
Extraordinary items	0	0	0	0	C
Tax expense	117,459	169,732	209,120	224,943	241,013
Minority interest	0	0	0	0	C
Income from JV/Associates	0	0	0	0	C
Reported PAT	390,943	502,325	620,720	667,687	715,389
PAT growth (%)	91.5	28.5	23.6	7.6	7.1
Adjusted PAT	390,943	502,325	620,720	667,687	715,389
Diluted EPS (Rs)	35.5	56.3	69.6	74.8	80.2
Diluted EPS growth (%)	55.2	58.6	23.6	7.6	7.1
DPS (Rs)	7.1	11.3	14.0	15.0	16.0
Dividend payout (%)	16.2	20.1	20.1	20.0	20.0
Effective tax rate (%)	23.1	25.3	25.2	25.2	25.2
Net interest margins (%)	2.8	3.0	3.0	3.0	3.0
Cost-income ratio (%)	53.3	53.9	53.9	53.5	52.4
Shares outstanding (mn)	8,924.6	8,924.6	8,924.6	8,924.6	8,924.6

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	8,925	8,925	8,925	8,925	8,925
Reserves & surplus	2,791,956	3,267,160	3,762,935	4,296,752	4,869,347
Net worth	2,800,881	3,276,085	3,771,860	4,305,677	4,878,271
Deposits	40,515,341	44,237,778	48,985,996	55,322,073	64,156,933
Borrowings	4,260,434	4,931,352	5,383,200	5,655,864	5,475,777
Interest bearing liab.	44.775.775	49.169.129	54.369.196	60,977,937	69.632.711
Other liabilities & prov.	2,299,318	2,724,571	3,184,236		4,189,754
Total liabilities & equity	49 875 974	55 169 785	61 325 291	68,994,215	78 700 736
Net advances	27,339,666		36,168,974		
Investments	14,814,455	15,703,662	16,963,503	18,474,729	20,415,858
Cash, other balances	3,945,523	3,078,996	3,262,152	3,658,676	4,177,963
Interest earning assets	46 000 644	E0 77E 2E1	E6 204 620	63,500,424	77 560 274
Fixed assets	377,082	423,818	482,201	529,307	581,049
Other assets	3,399,249	3,970,616	4,448,461	4,964,484	5,550,353
Total assets					
BVPS (Rs)	<b>49,875,974</b> 287.6	<b>55,169,785</b> 336.0	61,325,291 391.5	<b>68,994,215</b> 451.3	78,700,736 515.5
Adj. BVPS (INR)	264.2	318.0	374.6	433.3	492.0
Gross advances	28,180,239		36,773,221		
Credit to deposit (%)	67.5	72.3	73.8	74.8	74.8
CASA ratio (%)	44.5	42.7	40.5	39.9	39.9
Cost of deposits (%)	3.7	3.8	4.7	4.5	4.3
Loans-to-Assets (%)	54.8	58.0	59.0	60.0	61.0
Net advances growth (%)	11.6	17.0	13.1	14.4	16.0
Deposit growth (%)	10.1	9.2	10.7	12.9	16.0
Book value growth (%)	11.5	16.8	16.5	15.3	14.2
Source: Company, Emkay Rese	Parch				

Source: Company, Emkay Research

Asset quality and oth	er metric	5			
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Asset quality					
Gross NPLs	1,120,233. 7	909,281.5	805,662.1	770,073.1	933,418.8
Net NPLs	279,660.9	214,667.3	201,415.5	215,620.5	280,025.6
GNPA ratio (%)	4.0	2.8	2.2	1.8	1.9
NNPA ratio (%)	1.0	0.7	0.6	0.5	0.6
Provision coverage (%)	75.0	76.4	75.0	72.0	70.0
Gross slippages	250,212.3	192,230.0	246,380.6	314,411.0	413,345.7
Gross slippage ratio (%)	0.9	0.6	0.7	0.8	0.9
LLP ratio (%)	0.7	0.5	0.5	0.5	0.7
NNPA to networth (%)	10.1	6.6	5.3	5.0	5.7
Capital adequacy					
Total CAR (%)	13.8	14.7	14.2	13.6	12.8
Tier-1 (%)	11.4	12.1	11.9	11.6	11.1
CET-1 (%)	9.9	10.3	10.3	10.2	9.9
RWA-to-Total Assets (%)	55.0	50.5	53.0	55.0	57.0
Miscellaneous					
Total income growth (%)	2.4	16.7	23.1	8.5	9.8
Opex growth (%)	4.0	13.7	15.3	10.2	9.8
Core PPOP growth (%)	10.0	18.0	5.6	12.0	13.4
PPOP margin (%)	23.8	22.7	21.3	21.9	22.9
PAT/PPOP (%)	51.9	60.0	64.3	61.9	57.7
LLP-to-Core PPOP (%)	33.9	19.4	15.0	18.5	24.8
Yield on advances (%)	6.7	7.5	8.5	8.1	7.8
Cost of funds (%)	3.6	4.0	4.7	4.5	4.3

Source: Company, Emkay Research

Valuations and key Ratios								
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E			
P/E (x)	8.8	6.9	5.6	5.2	4.8			
P/B (x)	1.4	1.2	1.0	0.9	0.8			
P/ABV (x)	1.6	1.3	1.1	0.9	0.8			
P/PPOP (x)	2.2	2.0	1.7	1.5	1.3			
Dividend yield (%)	1.2	2.0	2.4	2.6	2.8			
DuPont-RoE split (%)								
NII/avg assets	2.5	2.8	2.8	2.8	2.7			
Other income	0.9	0.7	0.8	0.8	0.8			
Fee income	2.0	1.2	1.2	1.2	1.1			
Opex	1.8	1.9	1.9	1.9	1.8			
PPOP	1.6	1.6	1.7	1.7	1.7			
Core PPOP	1.5	1.6	1.5	1.5	1.5			
Provisions	0.5	0.3	0.2	0.3	0.4			
Tax expense	0.2	0.3	0.4	0.3	0.3			
RoA (%)	0.8	1.0	1.1	1.0	1.0			
Leverage ratio (x)	19.6	18.9	17.9	17.3	17.1			
RoE (%)	16.1	18.1	19.1	17.8	16.6			
Quarterly data								
Rs mn, Y/E Mar	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24			
NII	311,959	351,834	380,686	403,925	389,050			
NIM(%)	3.0	3.3	3.5	3.6	3.3			
PPOP	127,526	211,200	252,193	246,211	252,969			
PAT	60,681	132,645	142,053	166,945	168,843			
EPS (Rs)	6.80	14.86	15.92	18.71	18.92			

Source: Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **RECOMMENDATION HISTORY - DETAILS**

Date	CMP (INR)	TP (INR)	Rating	Analyst
19-May-23	575	700	Buy	Anand Dama
09-Mar-23	559	715	Buy	Anand Dama
04-Feb-23	544	715	Buy	Anand Dama
05-Nov-22	594	715	Buy	Anand Dama
06-Aug-22	531	640	Buy	Anand Dama
15-May-22	445	640	Buy	Anand Dama
24-Mar-22	487	680	Buy	Anand Dama
06-Feb-22	530	680	Buy	Anand Dama
03-Nov-21	528	680	Buy	Anand Dama
05-Jul-21	433	600	Buy	Anand Dama
23-May-21	401	600	Buy	Anand Dama
05-Feb-21	393	460	Buy	Anand Dama
20-Jan-21	303	340	Buy	Anand Dama
03-Jan-21	279	340	Buy	Anand Dama
05-Nov-20	219	265	Buy	Anand Dama

**RECOMMENDATION HISTORY - TREND** 



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO->.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits, Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of August 5, 2023
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of August 5, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the August 5, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

## Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.